US Oncology Gets Stockholder Approval, Completes Its Tender Offer and Closes Merger With Oiler Acquisition Corp. HOUSTON, Aug. 20 /PRNewswire-FirstCall/ -- US Oncology, Inc. (NASDAQ:USON) ("US...
Standard & Poor's Announces Change to S&P Index NEW YORK, Aug. 16 /PRNewswire/ -- Synaptics Inc. (NASDAQ:SYNA) will replace U.S. Oncology Inc. (NASDAQ:USON) in the S&P SmallCap 600 after the...
US Oncology Extends Tender Offer and Consent Solicitation for Its 9 5/8% Senior Subordinated Notes Due 2012 HOUSTON, Aug. 16 /PRNewswire-FirstCall/ -- US Oncology, Inc. (NASDAQ:USON) ("US...
US Oncology Reports Financial Results for Second Quarter 2004 HOUSTON, July 23 /PRNewswire-FirstCall/ -- US Oncology, Inc. (NASDAQ:USON) today reported results for the 2004 second quarter. The...
US Oncology Announces Proposed Offering of Notes HOUSTON, July 22 /PRNewswire-FirstCall/ -- US Oncology, Inc. ("US Oncology") (NASDAQ:USON) announced today that it is commencing an offering...
US Oncology Extends Tender Offer and Consent Solicitation for Its 9 5/8% Senior Subordinated Notes Due 2012 HOUSTON, July 19 /PRNewswire-FirstCall/ -- US Oncology, Inc. (NASDAQ:USON) ("US...
Patients With Advanced Breast Cancer Failed By Previous Treatment With Taxol and Taxotere Respond to Weekly Administration With the Investigational Agent Abraxane(TM) HOUSTON, June 14...
US Oncology Announces Receipt of Requisite Consents and Extends Tender Offer and Consent Solicitation for Its 9-5/8% Senior Subordinated Notes Due 2012 HOUSTON, June 14 /PRNewswire-FirstCall/...
US Oncology Extends Tender Offer and Consent Solicitation for Its 9 5/8% Senior Subordinated Notes Due 2012 HOUSTON, June 7 /PRNewswire-FirstCall/ -- US Oncology, Inc. (NASDAQ:USON...
Texas Oncology Participates in Testing of Major New Breast Cancer Treatment Regimen Study Could Change the Way Doctors Treat Many Breast Cancer Patients GARLAND, Texas, May 26 /PRNewswire/...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관